Clinical trial
An Open-label, Randomized, Single-dose Crossover Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD-388 in Healthy Subjects
NCT05189288 is registered in ClinicalTrials.gov with Chong Kun Dang Pharmaceutical as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-label, Randomized, Single-dose Crossover Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD-388 in Healthy Subjects
- Lead sponsor
- Chong Kun Dang Pharmaceutical
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- January 14, 2022
- Completion date
- April 15, 2022
- Enrollment
- 65 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
chronic hepatitis b